Nasonex Articles
Unigene gets approvable letter for Fortical
19 January 2004
Nascobal Nasal spray NDA submitted to FDA
5 January 2004
Nastech submits calcitonin nasal spray NDA
5 January 2004
Atrix gains appro for generic mometasone ointment
24 November 2003
FDA clears AstraZeneca's Zomig nasal spray
13 October 2003
Generics push S-P profits down 71%
28 July 2003
FDA OKs MedImmune and Wyeth's FluMist
30 June 2003
11 new drugs added to Japan's NHI price list
9 June 2003
IVAX seeks approval for generic Flonase
17 March 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
Flixonase goes OTC in UK
17 March 2003
Pfizer merger oked by EC but not without cost
10 March 2003
Pfizer/Pharmacia merger clears EU hurdle
3 March 2003
S-P launches Asmanex Twisthaler for asthma in UK
27 January 2003
Rigel starts US trial of allergy treatment
20 January 2003
S-P gains infant indication for Nasonex
29 July 2002
Inspire starts Phase II trial of rhinitis drug
13 May 2002
AstraZeneca's Zomig nasal spray gets first launch in Sweden
25 February 2002
S-P profits hit by charges
28 January 2002
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
IVAX acquires intranasals from Elan
26 September 2001
FDA responds to Aviron after FluMist review
5 September 2001
Inspire files IND for rhinosinusitis drug in USA
16 August 2001
Aviron's nasal flu vaccine turned down by FDA panel
30 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
Ph I results with Palatin's ED drug PT-141
7 June 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
Manufacturing woes hit Schering-Plough
18 April 2001
Aventis to boost Allegra production
16 March 2001
Schering-Plough EPS increases 14.7%
26 January 2001
AstraZeneca files for Zomig nasal spray
22 November 2000
S-P sales growth driven by Claritin
24 October 2000
Novartis' Miacalcic shows 36% reduction in fractures
19 October 2000
Stock Commentary Tokyo
5 October 2000
Schering-Plough net income up 16%
26 July 2000
Stock Commentary New York
20 July 2000
Palatin cleared to begin trials of PT-141
29 June 2000
Schering-Plough net income rises 16.5%
26 April 2000
S-P's Asmanex, data presented
8 March 2000
Hong Kong pharmacy call to ease OTC regs
1 March 2000
Agouron boosted on drug for common cold
16 December 1999
Nasonex approved for young children in EU
5 November 1999
Tamiflu approved in the USA
28 October 1999
Schering-Plough strong sales boost EPS
22 October 1999
Rhinocort Aqua approved in USA
11 October 1999
GW, S-P push steroids for allergic rhinitis
7 July 1999
Merck and Novartis battle over drug trial
17 June 1999
Agouron Unveils Common Cold Drug
13 October 1998
New Drugs, Vaccine Shift Balance In War Against Flu
30 September 1998
Major Vaccine Deals For France's Biovector
24 September 1998
Finland May Delay Approval Of Cortecs' Macritonin
17 September 1998
Novartis' Miacalcic Nasal Spray - Four-Year Results
17 September 1998
Aviron's FluMist "Non-Filable," Says FDA
2 September 1998
Solid 2nd Qtr For Schering-Plough
22 July 1998
New Indication Sought For Miacalcin
17 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
Naratriptan Launched In The USA
26 March 1998
Asta Comes Through Tough Year, Looks To Expansion
4 March 1998
GW's Naratriptan Approved In The USA
12 February 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
News In Brief
11 December 1997
GW's Nasal Spray Is Launched
4 December 1997
News In Brief
7 November 1997
Boehringer Ingelheim's BIRR 4 Cold Therapy
9 October 1997
FDA And GW Put Beconase OTC Switch On Hold
11 September 1997
GW's Imitrex Approved In USA
4 September 1997
P&U's Nicotrol Inhaler Launched In USA
19 May 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
S-P's Nasonex Cleared In First Markets
21 April 1997
R-PR Launches Nasacort In The UK
17 March 1997
Glaxo Wellcome Launches Imigran Nasal Spray In UK
10 March 1997
Carter-Wallace's Astelin Launched In USA
3 March 1997
S-P Targets Psoriasis With Mometasone
24 February 1997
GW's Imigran Approved In 12 EU Countries
6 January 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
R-PR Submits Two Supplementary NDAs
28 October 1996
S-P File NDA To FDA For Nasonex
14 October 1996
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
